CDA | Evidence Driven
CDA | Evidence Driven

Trifluridine and Tipiracil (Lonsurf) for Metastatic Colorectal Cancer Resubmission – Details

Details

Files
Generic Name:
Trifluridine and Tipiracil
Project Status:
Complete
Therapeutic Area:
mCRC Resubmission
Manufacturer:
Taiho Pharma Canada, Inc.
Brand Name:
Lonsurf
Project Line:
Reimbursement Review
Project Number:
PC0173-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
15 mg & 20 mg
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents
Sponsor:
Taiho Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – pERC Final Recommendation Final Recommendation August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Final Economic Guidance Report Guidance Reports August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Final Clinical Guidance Report Guidance Reports August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – pERC Initial Recommendation Initial Recommendation July 5, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – PAG Feedback on Initial Recommendation Feedback August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Manufacturer Feedback on Initial Recommendation Feedback August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Patient Advocacy Group Feedback on Initial Recommendation Feedback August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Clinician Feedback on Initial Recommendation Feedback August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Patient Advocacy Group COI Declarations COI Declarations August 29, 2019 View PDF
Trifluridine-Tipiracil (Lonsurf) mCRC Resubmission – Clinician COI Declarations COI Declarations August 29, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 19, 2019